Memorial Hospital Research Laboratories
The Charles Rudin Lab
Research
Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.
Featured News
Publications Highlights
Rekhtman et al., Chromothripsis-mediated small cell lung carcinoma. Cancer Discov 2024 (DOI: 10.1158/2159-8290.CD-24-0286).
Redin et al., SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol 2024 (DOI: 10.1186/s13045-024-01572-3).
Quintanal-Villalonga et al., CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal Transduct Target Ther 2024 (DOI: 10.1038/s41392-024-01908-y).
Rudin et al., Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J Thorac Oncol 2023 (DOI: 10.1016/j.jtho.2023.05.008).
People
Charles M. Rudin, MD, PhD
- Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
- MD, PhD, University of Chicago Pritzker School of Medicine
- [email protected]
- Email Address
- View physician profile
- Physician profile
Members
- Postdoctoral in Immunology from University of Sao Paulo / Memorial Sloan-Kettering Cancer Center
- PhD in Oncology from A. C. Camargo Hospital / MD Anderson Cancer Center
- MS in Oncology from Ludwig Institute for Cancer Research / A. C. Camargo Hospital
- BA, Macalester College
- Cancer Biology
- Residency, Cornell University (Internal Medicine)
- MD, PhD, Columbia University
- BS, Stanford University
- BS, Northeastern University
- BS, Northeastern University
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Charles M. Rudin discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Amgen
Professional Services and Activities -
Boehringer Ingelheim
Professional Services and Activities -
D2G Oncology
Professional Services and Activities -
Daiichi Sankyo
Intellectual Property Rights -
Earli Inc.
Equity
-
Harpoon Therapeutics, Inc.
Professional Services and Activities -
Jazz Pharmaceuticals
Professional Services and Activities -
Mariana Oncology, Inc.
Professional Services and Activities -
Scorpion Therapeutics, Inc.
Professional Services and Activities -
Treeline Biosciences, Inc.
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].